logo
ProjectActive

ACON Injectable Investors I, L.P.

Active · Colombia

Source: Deutsche Investitions- und Entwicklungsgesellschaft (DEG)

Established in 1999, Vitalis Group is a leading manufacturer and distributor of generic injectable pharmaceuti-cals with production facilities in Colombia and Mexico, and sales to more than 20 countries, focusing on Latin American. The Group’s more than 700 products are mainly used in surgical theaters, emergency rooms and intensive care units, including for treatment of Covid-19 patients. With ov

Status
Prospective
Sector
Industry
Location
Colombia
Updated
19 Nov 2026
Source
Deutsche Investitions- und Entwicklungsgesellschaft (DEG)

ConstructChat

Ask ConstructChat about ACON Injectable Investors I, L.P.

Pick a question to edit it, or write your own.

First answer free · no account

I am a

Project Information FAQ

Project Information

4 Q
The project “ACON Injectable Investors I, L.P.” is an infrastructure initiative in the Industry sector, located in Colombia. Taiyo aggregates data on it from Deutsche Investitions- und Entwicklungsgesellschaft (DEG).

Participants

Not available for this record.

Status

Original status

active

Taiyo status

Prospective

Taiyo last update

2026-11-19

Contact

Not available for this record.

Description

Description

Established in 1999, Vitalis Group is a leading manufacturer and distributor of generic injectable pharmaceuti-cals with production facilities in Colombia and Mexico, and sales to more than 20 countries, focusing on Latin American. The Group’s more than 700 products are mainly used in surgical theaters, emergency rooms and intensive care units, including for treatment of Covid-19 patients. With over 150 molecules in its portfolio, it covers multiple therapeutic areas such as antibiotics, anesthetics, analgesics, and gastrointestinal.The funds are used to acquire the companies that comprise Vitalis Group, ensure the continuation of business under a newly recruited CEO, and further institutionalize the company in preparation for future growth.With the Group’s products currently reaching approx. 50 million patients, its generic pharmaceuticals signifi-cantly contribute to providing long-term affordable healthcare solutions in the region, including treatment of Covid-19. Two thirds of the Group’s workforce is already comprised of female employees, and the creation of about 150 additional jobs is planned over the next five years. Vitalis Group is expected to grow its generation of local income by approx. 70% during DEG’s holding period thanks to production and personnel located in Colombia and Mexico.In cooperation with private equity manager ACON Investments, as well as FMO and PROPARCO, DEG pro-motes international standards of environmental and social management. DEG also supports the transition from a family-owned company to an institutionalized market player by and fostering the development of Vitalis Group’s corporate governance structures.The transaction fits DEG’s strategy to support mid-market companies. It contributes to enhance the availability of capital for the healthcare sector in Latin America and provides patients access to affordable generic phar-maceuticals. DEG also ensures the implementation of and adherence to high standards in terms of corporate governance and environmental and social practices.

Original sector

Industry

Budget

Location

Country

Colombia

Source

Source

Deutsche Investitions- und Entwicklungsgesellschaft (DEG)

URL

More Details

Record type

Project

Article published date

2024-05-29

More on this project

Research

Free account

View all details

You are reading the public part. A free account opens the rest:

  • Every detail on this project
  • News and media coverage
  • Technical research
View all details

Free account · no card · lands you back on this project